167 related articles for article (PubMed ID: 20944044)
21. Simultaneous bilateral atypical femoral fractures after alendronate therapy.
Zafeiris CP; Stathopoulos IP; Kourkoumelis G; Gkikas E; Lyritis GP
J Musculoskelet Neuronal Interact; 2012 Dec; 12(4):262-4. PubMed ID: 23196269
[No Abstract] [Full Text] [Related]
22. Compliance with treatment for osteoporosis.
Cooper A
Lancet; 2006 Nov; 368(9548):1648. PubMed ID: 17098078
[No Abstract] [Full Text] [Related]
23. Drug holidays in women treated for postmenopausal osteoporosis.
McClung MR
Menopause; 2018 Oct; 25(10):1152-1154. PubMed ID: 30044265
[TBL] [Abstract][Full Text] [Related]
24. [When should bisphosphonate treatment be discontinued?].
Eriksen EF; Halse J
Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
[No Abstract] [Full Text] [Related]
25. Alendronate-induced unmasking or deterioration of coeliac disease: a case series.
Stuckey BG; Sallie R
Osteoporos Int; 2015 Jan; 26(1):411-4. PubMed ID: 25349054
[No Abstract] [Full Text] [Related]
26. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical Femoral Nerve Study Following Bisphosphonates Administration.
Karakousis VA; Liouliou D; Loula A; Kagianni N; Dietrich EM; Meditskou S; Sioga A; Papamitsou T
Medicina (Kaunas); 2020 Mar; 56(3):. PubMed ID: 32204565
[No Abstract] [Full Text] [Related]
28. [Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
Ringe JD
MMW Fortschr Med; 2009 Mar; 151(10):7. PubMed ID: 19472655
[No Abstract] [Full Text] [Related]
29. Yearly zoledronic acid in postmenopausal osteoporosis.
Karam R; Camm J; McClung M
N Engl J Med; 2007 Aug; 357(7):712-3; author reply 714-5. PubMed ID: 17703529
[No Abstract] [Full Text] [Related]
30. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
31. Strontium ranelate treatment in a postmenopausal woman with osteonecrosis of the jaw after long-term oral bisphosphonate administration: a case report.
Pan WL; Chen PL; Lin CY; Pan YC; Ju YR; Chan CP; Hsu RW
Clin Interv Aging; 2017; 12():1089-1093. PubMed ID: 28744112
[TBL] [Abstract][Full Text] [Related]
32. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T
Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
[TBL] [Abstract][Full Text] [Related]
33. [Alendronate].
Lindberg M
Ugeskr Laeger; 1998 Oct; 160(44):6367-8. PubMed ID: 9810249
[No Abstract] [Full Text] [Related]
34. Safety considerations with bisphosphonates for the treatment of osteoporosis.
Strampel W; Emkey R; Civitelli R
Drug Saf; 2007; 30(9):755-63. PubMed ID: 17722968
[TBL] [Abstract][Full Text] [Related]
35. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
36. [Diphosphonate therapy and osteonecrosis of the jaw].
Løkken P; Skoglund LA; Skjelbred P
Tidsskr Nor Laegeforen; 2007 Aug; 127(15):1945-7. PubMed ID: 17700737
[No Abstract] [Full Text] [Related]
37. Bilateral distal fibula fractures in a woman on long-term bisphosphonate therapy.
Murray JC; Audet MC; Bédard M; Michou L
Osteoporos Int; 2016 Feb; 27(2):833-6. PubMed ID: 26556740
[TBL] [Abstract][Full Text] [Related]
38. Clinical Practice. Postmenopausal Osteoporosis.
Black DM; Rosen CJ
N Engl J Med; 2016 Jan; 374(3):254-62. PubMed ID: 26789873
[TBL] [Abstract][Full Text] [Related]
39. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
Bize R; Lamy O; Peytremann-Bridevaux I
Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
[No Abstract] [Full Text] [Related]
40. Bisphosphonates and the risk of atrial fibrillation.
Sewerynek E; Stuss M
Endokrynol Pol; 2011; 62(1):93-6. PubMed ID: 21365587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
